GlassScriptPhysician profile
Jack Klenda
NPI 1023677812
$1,059.22
in general payments reported to CMS, 2019-2025
13 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.46 · 2020: $129 · 2021: $243 · 2022: $25.00 · 2023: $123 · 2024: $390 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $248.68 | 2024 | |
| Alcon Vision LLC | $128.82 | 2022-2025 | Clareon, Hydrus Microstent, Simbrinza |
| Horizon Therapeutics Plc | $123.33 | 2023 | Tepezza |
| Dompe US, INC. | $122.83 | 2021 | |
| Apellis Pharmaceuticals, INC. | $122.12 | 2024 | Syfovre |
| Eyepoint US, INC. | $119.71 | 2021 | |
| Allergan, INC. | $99.99 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $17.55 | 2025 | Tecnis Iol |
| Glaukos Corporation | $17.32 | 2025 | Kxl System (Not Refurbished) |
| Clovis Oncology, INC. | $16.80 | 2019 | |
| Genzyme Corporation | $16.42 | 2020 | |
| Celgene Corporation | $12.99 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Klenda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.